Cardiovascular market replete with opportunities for drug developers, says analyst

15 March 2019

Although the cardiovascular market is very mature and heavily genericized, total sales of drugs for cardiovascular diseases will grow steadily over the next six years, from almost $47 billion in 2018 to over $70 billion in 2024.

An analysis of data from GlobalData’s Pharma Intelligence Center reveals that two anticoagulants -Bristol-Myers Squibb’s (NYSE: BMY) Eliquis (apixaban)‎ and Johnson & Johnson (NYSE: JNJ)]/Bayer’s (BAYN: DE) Xarelto (rivaroxaban), as well as Novartis’ heart failure drug Entresto (sacubitril/valsartan]), and two drugs for pulmonary arterial hypertension – J&J’s Uptravi (selexipag) and Opsumit (macitentan] - will be the top five major drivers of growth during this period.

Valentina Gburcik, director of cardiovascular and metabolic disorders at GlobalData, comments: “These five drugs will represent almost 50% of the total cardiovascular market in 2024, with Eliquis and Xarelto alone representing 36%. Cholesterol-lowering drugs were not part of this analysis, as they were considered to be part of the metabolic disorders therapeutic area.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK